PDCD1 and Miyoshi myopathy: To evaluate whether MT-HGs associate with outcomes of other frontline ICI therapies in MM, we tested MT-HG associations with the clinical efficacy of IPI-NIVO combination (anti-CTLA-4/anti-PD-1; COMBO), which is currently an approved SOC first-line ICI regimen for patients with MM.